Primary CNS neoplasms can rarely be associated with abnormal vascularity which is more striking than usual hypervascularity or neovascularization. These lesions are sometimes reported as angiogliomas, angiomatous astrocytomas, or descriptively as two distinct pathological entities. This vascular pattern has been reported with astrocytomas, oligodendrogliomas, neurilemmomas, meningiomas, pituitary adenomas, gangliogliomas, hemangioblastomas, mixed gliomas, gliosarcomas, and craniopharyngiomas. These lesions are classically found to be extremely vascular, both radiographically and at surgery. The true nature of these lesions is a point of controversy with some interpreting them merely as intensely vascularized tumors. Most agree, however, that unlike neovascularity in astrocytomas, the vascularity in these lesions does not carry any significant prognostic importance. In this report we present six such cases from The Children’s Hospital of Philadelphia seen in the pediatric population. Four patients had vascular malformations associated with diffuse astrocytomas, and in 2 patients they were associated with subependymal giant cell astrocytomas. Five of the lesions were supratentorial, and 1 was located in the posterior fossa. The history and theories surrounding these lesions are explored.

Keywords:
Glioma, Neoplasm, Cavernous angioma, Arterial venous malformation, Angioma
This content is only available via PDF.
© 1993 S. Karger AG, Basel
1993
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.